DLocal (DLO) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this online payment company would post earnings of $0.15 per share when it actually produced earnings of $0.15, delivering no surprise.Over the last four quarters, the company has sur ...

Fidelis Insurance Holdings (FIHL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.65%. A quarter ago, it was expected that this insurance and reinsurance company would post a loss of $1.08 per share when it actually produced a loss of $1.05, delivering a surprise of 2.78%.Over the last ...

Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 47.37%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.23, delivering a surprise of 34.29%.Over the last four quarters, the company ...

Steris (STE) came out with quarterly earnings of $2.74 per share, beating the Zacks Consensus Estimate of $2.59 per share. This compares to earnings of $2.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.79%. A quarter ago, it was expected that this medical products maker would post earnings of $2.32 per share when it actually produced earnings of $2.32, delivering no surprise.Over the last four quarters, the company has s ...

Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.46%. A quarter ago, it was expected that this company would post earnings of $0.56 per share when it actually produced earnings of $0.55, delivering a surprise of -1.79%.Over the last four quarters, the co ...

- Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. - Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and Priority Review from the FDA.- Troriluzole would be the first and only FDA-approved treatment for SCA, if approved.NEW HAVEN, Conn., May 14, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed th ...

I am an avid investor with a major focus on small cap companies with experience in investing in US, Canadian, and European markets. My investment philosophy to generating great returns on the stock market revolves around identifying mispriced securities by understanding the drivers behind a company's financials, and ultimately, most often revealed by a DCF model valuation. This methodology doesn't limit an investor into rigid traditional value, dividend, or growth investing, but rather accounts for all of a ...

Core Insights - POET Technologies Inc. reported significant financial improvements in Q1 2025, including a net income of $6.3 million compared to a net loss of $5.7 million in Q1 2024 [5][10] - The company is focusing on technology innovation, commercial progress, and strategic partnerships to drive revenue growth in the second half of 2025 [2][4] Financial Performance - The company achieved non-recurring engineering and product revenue of $166,760 in Q1 2025, a substantial increase from $8,710 in Q1 2024 and $29,032 in Q4 2024 [4][13] - Research and development costs rose to $4.3 million in Q1 2025 from $1.9 million in Q1 2024, reflecting the transition from technology development to product development [5][13] - A significant non-cash gain of $15.4 million from fair value adjustments to derivative warrant liability was recorded in Q1 2025, compared to a loss of $630,000 in Q1 2024 [6][13] Business Highlights - The company opened a 10,000 square foot clean room in Malaysia to enhance production capacity for AI and cloud data center customers [2] - POET shipped final design samples of its POET Infinity transmit product line for 400G and 800G applications to major technology leaders [8] - The company partnered with Lessengers to offer an 800G DR8 transceiver, enhancing its product offerings in the optical solutions market [8] Cash Flow and Other Income - Cash flow from operating activities was negative $8.9 million in Q1 2025, compared to negative $4.6 million in Q1 2024 [10] - The company recognized other income, including interest of $528,000 in Q1 2025, up from $52,000 in Q1 2024 [9][13]

Group 1: Earnings Performance - GCT Semiconductor Holding, Inc. reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, representing an earnings surprise of -50% [1] - The company posted revenues of $0.5 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 73.48%, compared to revenues of $3.27 million a year ago [2] - Over the last four quarters, GCT Semiconductor has surpassed consensus EPS estimates only once [2] Group 2: Stock Performance and Outlook - GCT Semiconductor shares have declined approximately 27.9% since the beginning of the year, while the S&P 500 has gained 0.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.11 on revenues of $3.2 million, and -$0.25 on revenues of $37.18 million for the current fiscal year [7] Group 3: Industry Context - The Electronics - Semiconductors industry, to which GCT Semiconductor belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact GCT Semiconductor's stock performance [5] - The Zacks Rank for GCT Semiconductor is currently 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Core Insights - Clearside Biomedical, Inc. reported a quarterly loss of $0.11 per share, which was better than the Zacks Consensus Estimate of a loss of $0.12, and an improvement from a loss of $0.17 per share a year ago [1] - The company achieved revenues of $2.33 million for the quarter ended March 2025, significantly surpassing the Zacks Consensus Estimate by 785.93%, compared to revenues of $0.23 million in the same quarter last year [2] - The stock has underperformed the market, losing about 5.3% since the beginning of the year, while the S&P 500 gained 0.1% [3] Financial Performance - Over the last four quarters, Clearside Biomedical has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $0.26 million, and for the current fiscal year, it is -$0.45 on revenues of $1.19 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Clearside Biomedical belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Clearside Biomedical's stock performance [5]